AIDS Research and Discovery


   AIDFAREL(TM) inhibits both the replication and transcription of the
 integrated viral DNA known as a provirus by using the drug technology termed
 Binary Molecular DNA Clamp (BMC). The drug consists of two similar but
 distinct parts that can be "programmed" to bind any specific Double Stranded
 DNA (dsDNA) sequence, in any gene. In CD4 T-cells infected with the virus,
 the drug is set to bind to where the tat and rev genes overlap. Once bound to
 the specified DNA sequence, the two parts react with each other to become
 one molecule that surrounds the target DNA molecular sequence, completely
 preventing transcription and translation of that region and shutting down all
 viral production permanently.
AIDFAREL(TM) is unique in that it only needs to be given three times over
 a one-month period, making the treatment process significantly less taxing for
 patients. Complete reconstitution of the immune system should occur within
 four to six weeks of the first intravenous injection of AIDFAREL(TM).

Binary Molecular DNA Clamp drug technology represents a promising new form
of anti-retroviral chemotherapy, for AIDS, other genetic disorders,
tissue-organ rejection and as a new laboratory tool in the study of molecular